Llwytho...

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers

Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, up...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Pharmacol Drug Dev
Prif Awduron: Kotani, Naoki, Yoneyama, Koichiro, Kawakami, Nobuhiko, Shimuta, Tohru, Fukase, Hiroyuki, Kawanishi, Takehiko
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767117/
https://ncbi.nlm.nih.gov/pubmed/30230257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.617
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!